Dostarlimab-gxly

Dostarlimab-gxly Uses, Dosage, Side Effects, Food Interaction and all others data.

Dostarlimab-gxly is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt to destroy the cancerous cells. Agents acting on the PD-1 pathway, such as nivolumab and pembrolizumab, facilitate endogenous immune-mediated anti-tumor activity and may therefore be used to treat a wide variety of cancers, including those of the skin, lung, kidneys, and liver.

In April 2021, dostarlimab was granted an accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer experiencing disease progression despite treatment with platinum-containing chemotherapy regimens. As this accelerated approval was granted only for the treatment of dMMR endometrial cancers, it was approved alongside a companion diagnostic device - the VENTANA MMR RxDx Panel - for use in selecting appropriate patients for treatment.

Dostarlimab-gxly is an immunotherapy that facilitates the body's endogenous anti-tumor immune response in the treatment cancer. It is administered over a span of 30 minutes via intravenous infusion every three to six weeks depending on the cycle.

Trade Name Dostarlimab-gxly
Availability Prescription only
Generic Dostarlimab
Dostarlimab Other Names Dostarlimab, dostarlimab-gxly, Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Related Drugs methotrexate, Keytruda, medroxyprogesterone, megestrol, hydroxyurea, pembrolizumab, Provera, Lenvima, Hydrea, Jemperli
Type
Formula C6420H9832N1680O2014S44
Weight 144000.0 Da (non-glycosylated)
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Dostarlimab-gxly
Dostarlimab-gxly

Uses

Dostarlimab-gxly is an anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.

Dostarlimab-gxly-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.

Dostarlimab-gxly is also used to associated treatment for these conditions: Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer

How Dostarlimab-gxly works

Approximately 13-30% of recurrent endometrial cancers involve microsatellite instability (MSI) or mismatch repair deficiency (dMMR). The mutations resulting in dMMR endometrial cancers are primarily somatic in nature (~90%), although 5-10% of cases involve germline mutations. Cancers that have mutations resulting in dMMR can upregulate the expression of programmed death receptor-1 (PD-1) ligands 1 and 2 (PD-L1 and -L2) - PD-1 is found on T-cells and, when activated, inhibits their proliferation and the production of cytokines. The binding of these ligands to PD-1 thereby functions as an immune checkpoint that downregulates the anti-tumor immune response.

Dostarlimab-gxly is a monoclonal antibody targeted against PD-1 - it binds to the receptor and prevents interactions with PD-L1 and PD-L2, thus allowing the anti-tumor immune response to proceed unimpeded.

Toxicity

There are no data regarding overdose with dostarlimab. Symptoms of overdosage are likely to be consistent with the adverse effect profile of dostarlimab and may therefore involve significant immune-mediated reactions.

Food Interaction

No interactions found.

Volume of Distribution

At steady-state, the mean volume of distribution of dostarlimab is 5.3L.

Elimination Route

During the first cycle, and administered at 500mg intravenously every 3 weeks, the mean Cmax and AUC0-tau of dostarlimab-gxly are 171 mcg/mL and 35,730 mcg.h/mL, respectively. When administered at 1000mg every 6 weeks, the mean Cmax and AUC0-tau are 309 mcg/mL and 95,820 mcg.h/mL, respectively.

Half Life

The mean terminal elimination half-life of dostarlimab is 25.4 days.

Clearance

At steady-state, the mean clearance of dostarlimab is 0.007 L/h.

Innovators Monograph

You find simplified version here Dostarlimab-gxly

*** Taking medicines without doctor's advice can cause long-term problems.
Share